Royalty Report: Drugs, Therapeutic, Disease – Collection: 203313


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 4


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 4

Primary Industries

  • Drugs
  • Therapeutic
  • Disease
  • Pharmaceuticals
  • Diagnostic

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 203313

License Grant
Licensor grants an exclusive, even as to Licensor, world-wide license under the Patent Rights and the Know-How to develop, make, have made, use, sell, have sold, offer for sale, import or otherwise commercialize Licensed Products and Improvements in the Field.
License Property
The Compounds shall mean doxepin, amitriptyline, trimipramine, trazodone and nortriptyline, as well as any respective prodrugs, hydrates, salts, esters, isomers, polymorphs or analogues thereof.

'Patent Rights' shall mean (i) U.S. Patent Nos. 5,502,047, 5,643,897, 6,211,229 and 6,344,487

Field of Use
The Field shall mean the prevention, treatment or control of insomnia, and any other use of the Compounds within the Ranges.

IPSCIO Record ID: 233451

License Grant
Licensor grants a worldwide, exclusive license, with the right to sublicense, under the Licensors Rights, to Develop, make, have made, use, sell, offer for sale, have sold and import the Compound and Products in the Field, and otherwise to perform its obligations expressly set forth in this Agreement and the Co-Promotion Agreement.
License Property
The Compound means either (a) the Initial Compound or (b) any compound that is claimed in U.S. Patent No. 6,288,122 Bl and any hydrates, anhydrides, solvates, salts, esters or polymorphs thereof.

The initial compound means the compound ICA-17043 having the molecular structure set forth and any hydrates, anhydrides, solvates, salts, esters, isomers, prodrugs, metabolites or polymorphs thereof.

The Product means a pharmaceutical product that contains, incorporates or is comprised of the Compound, whether in development or approved by any Regulatory Authority, including all formulations, line extensions and modes of administration thereof.

The Licensor Patents means all Patents, other than CMCC Patents, Controlled by Licensor as of the Effective Date or during the Term, that, absent rights thereunder, would be infringed by the Development, Manufacture, formulation, use, distribution, importation, sale, or offer for sale of Compound or Product, including without limitation any such Patents claiming the composition of matter or the use of Compound or Product or any Improvements thereto.

Licensors know-how means all Information, except for CMCC Know-How, that Licensor Controls as of the Effective Date or during the Term.

Field of Use
The field means prevention and treatment of all human and animal diseases and disorders.  The licensed technology is for use of these compounds include treating sickle cell disease, preventing erythrocyte dehydration and inhibiting potassium flux.

IPSCIO Record ID: 6792

License Grant
Licensor and Licensee are parties to that certain License Agreement dated August 25, 2003, as amended, which agreement the parties now wish to amend and restate in its entirety with this Agreement.

During the Term, Licensor grants to Licensee an exclusive, world-wide license under the Patent Rights and the Know-How to develop, make, have made, use, sell, have sold, offer for sale, import or otherwise commercialize Licensed Products and Improvements in the Field.  For the avoidance of doubt, the scope of the Licensee Licenses shall extend to Combination Products. Licensee may sublicense the Licensee Licenses to any third party, however, such sublicense(s) shall not relieve Licensee of its obligations to Licensor under this Agreement. Licensee shall promptly inform Licensor of the issuance of all such sublicenses.

Licensor shall promptly deliver to Licensee or provide Licensee with copies of (1) all documents, drawings, specifications, programs, devices and equipment relating to, and all other tangible manifestations of, the Know-How; and (2) all patent applications for which U.S. and international patents have not issued included in the Patent Rights.

License Property
Patent Rights shall mean (i) U.S. Patent Nos. 5,502,047, 5,643,897, 6,211,229 and 6,344,487; (ii) all other existing U.S. and international patents and/or patent applications now owned, co-owned, licensed or controlled by Licensor directed to the Compounds within the Ranges; and (iii) all U.S. and international patent applications and patents on Improvements owned, co-owned, licensed or controlled by Licensor during the Term. For the avoidance of doubt, the existing patent applications referenced in the agreement shall include, but not be limited to, the rights of Licensor in the following patent applications

(a) U.S. patent application number 12/446,914,
(b) U.S. patent application number 11/804,722,
(c) U.S. patent application number 11/804,720,
(d) Japanese patent application number 2009-511109,
(e) Canadian patent application number 2687118,
(f) U.S. patent application number 11/867,595,
(g) U.S. patent application number 12/535,640
(h) U.S. patent application number 12/535,623
(i) U.S. patent application number 12/517,507,
(j) U.S. patent application number 12/301,223,
(k) E.P.O. patent application number 7,795,135.8,
(l) Japanese patent application number 2009-511110, and
(m) Canadian patent application number 2687124.

Field of Use
U.S. Patent Nos. 5,502,047, 5,643,897, 6,211,229 and 6,344,487 refer to methods for the treatment of chronic insomnia and a method for the treatment of a patient suffering from transient or short term insomnia.

IPSCIO Record ID: 211925

License Grant
The Canadian Licensor grants an exclusive license under the Licensors Technology to use, market, advertise, promote, distribute, offer for sale, sell, manufacture, have manufactured, export and import, and co-develop the Product in the Territory for use in the Field with the right to sublicense.
License Property
The license includes patent rights and know-how for the compound.

The product is the proprietary compound known as ORI-9020.  ORI-9020 means ORI-9020 and its analogs, the chemical composition of which are described in the patent and any prodrug, metabolite, analog, salt, hydrate, solvate, polymorph, chimeric or inverted chimeric or isomer of ORI-9020.

Field of Use
The Field means the use of Product in the diagnosis and/or treatment of Hepatitis B infection.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.